Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Mri Features and Disability in Multiple Sclerosis: A Systematic Review and Meta-Analysis Publisher Pubmed



Nabizadeh F1 ; Zafari R2 ; Mohamadi M1 ; Maleki T2 ; Fallahi MS2 ; Rafiei N3
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Neuroradiology Published:2024


Abstract

Background: In this systematic review and meta-analysis, we aimed to investigate the correlation between disability in patients with Multiple sclerosis (MS) measured by the Expanded Disability Status Scale (EDSS) and brain Magnetic Resonance Imaging (MRI) features to provide reliable results on which characteristics in the MRI can predict disability and prognosis of the disease. Methods: A systematic literature search was performed using three databases including PubMed, Scopus, and Web of Science. The selected peer-reviewed studies must report a correlation between EDSS scores and MRI features. The correlation coefficients of included studies were converted to the Fisher's z scale, and the results were pooled. Results: Overall, 105 studies A total of 16,613 patients with MS entered our study. We found no significant correlation between total brain volume and EDSS assessment (95 % CI: -0.37 to 0.08; z-score: -0.15). We examined the potential correlation between the volume of T1 and T2 lesions and the level of disability. A positive significant correlation was found (95 % CI: 0.19 to 0.43; z-score: 0.31), (95 % CI: 0.17 to 0.33; z-score: 0.25). We observed a significant correlation between white matter volume and EDSS score in patients with MS (95 % CI: -0.37 to -0.03; z-score: -0.21). Moreover, there was a significant negative correlation between gray matter volume and disability (95 % CI: -0.025 to -0.07; z-score: -0.16). Conclusion: In conclusion, this systematic review and meta-analysis revealed that disability in patients with MS is linked to extensive changes in different brain regions, encompassing gray and white matter, as well as T1 and T2 weighted MRI lesions. © 2023 Elsevier Masson SAS
Related Docs
View other Related Docs
1. Neuroimaging Markers and Disability Scales in Multiple Sclerosis: A Systematic Review and Meta-Analysis, PLoS ONE (2024)
2. T1 and T2 Weighted Lesions and Cognition in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Journal of Clinical Neuroscience (2024)
3. Thalamic Asymmetry in Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2023)
4. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
5. Disability Outcomes of Early Cerebellar and Brainstem Symptoms in Multiple Sclerosis, Multiple Sclerosis Journal (2021)
6. Time Interval Between the Onset of Symptoms and Diagnosis of Multiple Sclerosis and the Influential Factors: A National Registry-Based Study, Clinical Neurology and Neurosurgery (2024)
7. Safety and Efficacy of Cladribine in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Neurological Sciences (2023)
8. Optical Coherence Tomography (Oct) Measurements and Disability in Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Journal of the Neurological Sciences (2023)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (133)
Masoud Etemadifar (98)
Other Related Docs
9. Cognitive Performance and Magnetic Resonance Imaging in People With Multiple Sclerosis: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2024)
10. Confirmed Disability Progression As a Marker of Permanent Disability in Multiple Sclerosis, European Journal of Neurology (2022)
11. Convergent Effects of a Functional C3 Variant on Brain Atrophy, Demyelination, and Cognitive Impairment in Multiple Sclerosis, Multiple Sclerosis Journal (2019)
12. Diagnostic Performance of Artificial Intelligence in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Neurological Sciences (2023)
13. Conversion From Radiologically Isolated Syndrome to Multiple Sclerosis, International Journal of Preventive Medicine (2014)
14. Study of Type a and B Behavior Patterns in Patients With Multiple Sclerosis in an Iranian Population, International Journal of Preventive Medicine (2013)
15. Comparison of Susceptibility Weighted Imaging With Conventional Mri Sequences in Multiple Sclerosis Plaque Assessment: A Cross-Sectional Study, Journal of Research in Medical Sciences (2021)
16. The Relationship Between Cognitive Disorders and Hippocampal Angle in Patients Multiple Sclerosis, Journal of Isfahan Medical School (2019)
17. Detection of Multiple Sclerosis Lesions by Susceptibility-Weighted Imaging—A Systematic Review and Meta-Analyses, Clinical Radiology (2024)
18. Dysphagia in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis: A Comparison of Frequency, Severity, and Effects on Quality of Life, Multiple Sclerosis and Related Disorders (2024)
19. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Neurology and Therapy (2022)
20. The Kurtzke Edss Rank Stability Increases 4 Years After the Onset of Multiple Sclerosis: Results From the Msbase Registry, Journal of Neurology, Neurosurgery and Psychiatry (2012)
21. Psychometric Assessment of the Persian Version of the Patient Determined Disease Steps Scale in Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder, Current Journal of Neurology (2022)
22. Variability of the Response to Immunotherapy Among Subgroups of Patients With Multiple Sclerosis, European Journal of Neurology (2023)
23. Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis, Acta Medica Iranica (2019)
24. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
25. Disability Accrual in Primary and Secondary Progressive Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2023)
26. Efficacy and Safety of Rituximab in Multiple Sclerosis: A Systematic Review and Meta-Analysis, Acta Neurologica Belgica (2023)
27. Prevalence of Multiple Sclerosis in Isfahan, Iran, Neuroepidemiology (2006)
28. Prevalence and Risk Factors of Dysphagia in Patients With Multiple Sclerosis, Dysphagia (2022)
29. First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis, Neurotherapeutics (2025)
30. Prevalence of Dysphagia in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis, Journal of Clinical Neuroscience (2023)
31. Association of Helicobacter Pylori With Multiple Sclerosis: Protective or Risk Factor?, Current Journal of Neurology (2020)
32. Multiple Sclerosis Severity Score (Msss) Improves the Accuracy of Individualized Prediction in Ms, Multiple Sclerosis Journal (2022)
33. Comparison of Disability in Patients With Multiple Sclerosis With and Without Familial History, Journal of Isfahan Medical School (2022)
34. Cognitive Function and Brain Magnetic Resonance Imaging Profiles in Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis, Journal of Research in Medical Sciences (2024)
35. The Effect of Ginger (Zingiber Officinale) Supplementation on Clinical, Biochemical, and Anthropometric Parameters in Patients With Multiple Sclerosis: A Double-Blind Randomized Controlled Trial, Food and Function (2023)
36. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
37. Stability of Mental Toughness, Sleep Disturbances, and Physical Activity in Patients With Multiple Sclerosis (Ms)-A Longitudinal and Pilot Study, Frontiers in Psychiatry (2018)
38. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)
39. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years, Neurology (2021)
40. Effect of Deep Gray Matter Atrophy on Information Processing Speed in Early Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2023)
41. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
42. The Frequency of Cognitive Dysfunction Among Multiple Sclerosis Patients With Mild Physical Disability, Journal of Isfahan Medical School (2012)
43. Risk Factors of Multiple Sclerosis and Their Relation With Disease Severity: A Cross-Sectional Study From Iran, Archives of Iranian Medicine (2016)
44. Magnetic Resonance Imaging-Based Biomarkers of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis, Journal of Neurology (2025)
45. Demographic and Clinical Characteristics of Familial and Sporadic Multiple Sclerosis Patients, International Journal of Preventive Medicine (2023)
46. Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis, JAMA Neurology (2018)
47. Effect of Donepezil on Cognitive Impairment, Quality of Life, and Depression in Multiple Sclerosis Patients: A Randomized Clinical Trial, International Journal of Preventive Medicine (2020)
48. Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis: A Randomized Clinical Trial, Acta Neurologica Scandinavica (2021)
49. Comparison of Prevalence Rates of Restless Legs Syndrome, Self-Assessed Risks of Obstructive Sleep Apnea, and Daytime Sleepiness Among Patients With Multiple Sclerosis (Ms), Clinically Isolated Syndrome (Cis) and Neuromyelitis Optica Spectrum Disorder (Nmosd), Sleep Medicine (2020)
50. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018, CNS Drugs (2021)